Does Cramer’s ‘Great, Great Speculation’ Tag Alter SI-BONE’s Risk Narrative and Niche Thesis (SIBN)?

In early January 2026, Jim Cramer described SI-BONE as a “great, great speculation” on his show’s lightning round, spotlighting its minimally invasive implants for sacroiliac joint dysfunction and ...

Jim Cramer on SI-BONE: "This is a great, great speculation"

SI-BONE, Inc. (NASDAQ:SIBN) is one of the stocks Jim Cramer shared his takes on. A caller asked about the company during the ...
Business Insider

SI-Bone’s Resilient Growth: Craig Bijou’s Buy Rating Reinforced by Strategic Positioning and Financial Trajectory

Bank of America Securities analyst Craig Bijou reiterated a Buy rating on SI-Bone (SIBN – Research Report) today and set a price target of $21.00. Craig Bijou has given his Buy rating due to a ...

Why Did SI-Bone (SIBN) Surge Spike After Hours?

SI-Bone shares rose in after-hours trading as three executives sold stock last week to cover RSU tax obligations.
Nasdaq

SI-BONE, Inc. to Release Fourth Quarter and Full Year 2024 Financial Results on February 24, 2025

SI-BONE, Inc., a company focused on medical technologies for sacropelvic disorders, announced it will release its financial results for the fourth quarter and full year of 2024 on February 24, 2025, ...
Nasdaq

SI-BONE, Inc. Reports Fourth Quarter and Full Year 2024 Financial Results, Achieving Significant Revenue Growth and Positive Adjusted EBITDA

SI-BONE reports strong revenue growth and improved financial metrics for Q4 2024 and FY 2024, achieving positive adjusted EBITDA. SI-BONE, Inc. reported strong financial results for the fourth quarter ...
Yahoo Finance

SI-BONE To Present at Piper Sandler 37th Annual Healthcare Conference on December 2, 2025

SANTA CLARA, Calif., Nov. 18, 2025 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving sacropelvic disorders, today announced that the company will be ...
Seeking Alpha

SI-BONE, Inc. Reports Record Financial Results for the Fourth Quarter 2024 and Issues 2025 Guidance

SANTA CLARA, Calif., Feb. 24, 2025 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (SIBN), a medical device company dedicated to solving sacropelvic disorders, today reported financial results for the fourth ...
Seeking Alpha

SI-BONE, Inc. Reports Financial Results for the First Quarter 2025 and Updates 2025 Guidance

Over 1,400 active U.S. physicians with 300 physicians added in the quarter, representing 27.3% growth CMS FY 2026 proposed hospital inpatient rule for New Technology Add-On Payment (“NTAP”) effective ...

SI-Bone (SIBN) Gets a Buy from Canaccord Genuity

Canaccord Genuity analyst Caitlin Cronin maintained a Buy rating on SI-Bone today and set a price target of $27.00. According to TipRanks, Cronin is a 4-star analyst with an average return of 15.7% ...
The Motley Fool

Why Shares of Si-Bone Jumped Tuesday

Si-Bone makes the iFuse Implant System for the sacroiliac joint, found in the lower back. The company said it increased its surgeon base to 950 surgeons in the U.S. Revenue for Si-Bone was up 46% year ...